Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer (NRR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00483405
Recruitment Status : Completed
First Posted : June 7, 2007
Results First Posted : May 9, 2017
Last Update Posted : July 12, 2017
Roche Pharma AG
Bristol-Myers Squibb
National Center for Research Resources (NCRR)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
UNC Lineberger Comprehensive Cancer Center

June 6, 2007
June 7, 2007
March 28, 2017
May 9, 2017
July 12, 2017
October 2006
February 2010   (Final data collection date for primary outcome measure)
Disease Response Rate [ Time Frame: 42 days (2 cycles) ]

Radiographic response will be measured every six weeks while subject is on treatment. Response will be measured using RECIST criteria.

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions.

Response every 6 weeks during treatment
Complete list of historical versions of study NCT00483405 on Archive Site
  • Number of Subjects Experiencing Adverse Events [ Time Frame: every 3 weeks of treatment with an average of 15 weeks on treatment ]
    Adverse events will be assessed using CTCAE criteria.
  • Overall Survival [ Time Frame: Median 23 month follow-up ]
    Overall survival will be calculated from time of enrollment to death or last contact date.
  • Time to Progression [ Time Frame: Median 23 month follow-up ]
    Time to progression will be calculated from the time of enrollment until confirmed disease progression. Defined by RECIST (Response Evaluation Criteria in Solid Tumors), Progressive Disease (PD) - at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.
  • Safety every 3 weeks during treatment
  • Survival
  • Time to Progression
Not Provided
Not Provided
Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer
Phase II Study of Oxaliplatin, Capecitabine, and Cetuximab in Advanced Hepatocellular Carcinoma

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving chemotherapy together with a monoclonal antibody may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving oxaliplatin and capecitabine together with cetuximab works in treating patients with advanced liver cancer.



  • Determine the response rate in patients with advanced hepatocellular carcinoma and hepatic dysfunction treated with oxaliplatin, capecitabine, and cetuximab.


  • Determine the safety of this regimen in these patients.
  • Determine the overall survival of patients treated with this regimen.
  • Determine the time to tumor progression in patients treated with this regimen.

OUTLINE: This is an open label, nonrandomized study.

Patients receive oral capecitabine twice daily on days 1-14, cetuximab IV over 60-120 minutes on days 1, 8, and 15, and oxaliplatin IV over 120 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed at 3-4 weeks and then every 3 months thereafter.

Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Liver Cancer
  • Biological: cetuximab
    250 mg/m2, intravenously, once per week
    Other Name: Erbitux
  • Drug: capecitabine
    850 mg/m2, orally, twice daily (dose rounded to accommodate 150 mg and 500 mg tablet sizes. Capecitabine given on days 1-14 of 21 day cycle.
    Other Name: Xeloda
  • Drug: oxaliplatin
    130 mg/m2, intravenously on Day 1 of each 21 day cycle
    Other Name: Eloxatin
Single Arm Trial
Single Arm Trial
  • Biological: cetuximab
  • Drug: capecitabine
  • Drug: oxaliplatin
Sanoff HK, Bernard S, Goldberg RM, Morse MA, Garcia R, Woods L, Moore DT, O'Neil BH. Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma. Gastrointest Cancer Res. 2011 May;4(3):78-83.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
December 2010
February 2010   (Final data collection date for primary outcome measure)


  • Meets 1 of the following criteria:

    • Histologically confirmed hepatocellular carcinoma
    • Alpha-fetoprotein (AFP) > 400 ng/mL with compatible mass by CT scan or MRI
  • Metastatic disease OR not a candidate for surgical resection or immediate liver transplantation
  • At least 1 site of measurable disease OR evaluable disease (AFP 2 times upper limit of normal (ULN))
  • No evidence of central nervous system (CNS) metastases (unless CNS metastases stable for > 3 months)


  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Absolute neutrophil count (ANC) ≥ 1,500/mm³
  • Hemoglobin ≥ 9 g/dL
  • Platelet count ≥ 100,000/mm³
  • Bilirubin ≤ 3 times ULN
  • International normalized ratio (INR) ≤ 1.5
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 times ULN
  • Creatinine clearance > 50 mL/min
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No known hypersensitivity to capecitabine, cetuximab, or oxaliplatin or to other murine products
  • No comorbid condition which is deemed by the investigator to have a life expectancy of < 6 months
  • No New York Heart Association class III-IV coronary artery disease and/or heart failure
  • No variceal bleeding within the past 60 days
  • No other cancer within the past 5 years except cervical intraepithelial neoplasia, nonmelanoma skin cancer, ductal carcinoma in situ, chronic lymphocytic leukemia, or treated localized prostate cancer with a normal prostate specific antigen level
  • No active drug or alcohol abuse
  • No prior allergic reaction to a therapeutic antibody
  • No serious, uncontrolled infection
  • No history of uncontrolled seizures, CNS disorders, or psychiatric disability that, in the opinion of the investigator, would preclude study participation or compliance
  • No other serious uncontrolled medical condition that, in the opinion of the investigator, would preclude study participation
  • No lack of physical integrity of the upper gastrointestinal tract
  • No malabsorption syndrome
  • No known existing uncontrolled coagulopathy


  • At least 4 weeks since prior participation in an investigational drug trial
  • At least 4 weeks since prior major surgery and recovered
  • At least 4 weeks since prior embolization, resection, or ablation
  • No prior epidermal growth factor receptor (EGFR)-targeting therapy
  • No prior systemic chemotherapy or hepatic artery infusion of chemotherapy
  • No concurrent phenytoin
  • No concurrent therapeutic warfarin

    • Low-dose non-therapeutic warfarin to maintain patency of venous access devices allowed
Sexes Eligible for Study: All
18 Years to 120 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
LCCC 0421
KL2RR025746 ( U.S. NIH Grant/Contract )
5K23CA118431-02 ( U.S. NIH Grant/Contract )
Not Provided
Plan to Share IPD: No
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
  • Sanofi
  • Roche Pharma AG
  • Bristol-Myers Squibb
  • National Center for Research Resources (NCRR)
  • National Cancer Institute (NCI)
Principal Investigator: Bert H. O'Neil, MD UNC Lineberger Comprehensive Cancer Center
Principal Investigator: Michael A. Morse, MD Duke University
UNC Lineberger Comprehensive Cancer Center
June 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP